0 %

About us

LaCAR is a company dedicated to transforming global public health through cutting-edge diagnostic solutions.

Our innovative technologies and responsive support enable laboratories to provide accurate and accessible care, contributing to a better quality of life for all.

LaCar team
Advancing health, improving life

Since 2013, LaCAR has been offering complete and integrated diagnostic solutions, with kits, software and automated machines perfectly adapted to the needs of laboratories.

Discover the LaCAR journey

Company’s creation 2013

LaCAR is a Belgian company that was created in Liège in December 2013 by various stakeholders from Liège's economic and scientific networks. The development of LaCAR was carried out in collaboration with the genetic unit of the University of Liège, which displays an international reputation and extensive expertise in the detection of genetic diseases.

Newborn Screening, Pharmacogenetics, and Predispositions & Disorders
1st CE-IVD ISO13485 2016

LaCAR achieves CE-IVD ISO 13485 certification for its first kit, marking a significant milestone in its commitment to quality and compliance with international standards.

Newborn screening solutions
European expansion 2020

LaCAR extends its reach internationally by exporting its products throughout Europe, consolidating its position as a key player in the field of diagnostic solutions.

Newborn screening solutions - LaCar
Acquisition of Biosense (Italy) 2021

The acquisition of Biosense has enabled us to establish a presence in Italy, allowing us to participate in public tenders. This step aligns perfectly with our commitment to expansion.

Newborn Screening, Pharmacogenetics, and Predispositions & Disorders
Acquisition of ZenTech (Belgium) 2022

ZenTech is a Belgian company specialised in newborn screening since 2001. In 2022, LaCAR and ZenTech merged their activities to combine their expertise in in vitro diagnostics (IVD) and their in-depth knowledge of the market.

Newborn screening solutions
Acquisition of Baebies, Inc.'s Newborn Screening Division in the U.S. 2025

Based in the U.S., Baebies is known for its innovations in newborn screening, particularly with its SEEKER solution dedicated to detecting Lysosomal Storage Diseases (LSD). Through this acquisition, LaCAR integrates cutting-edge screening technology, extending the number of diseases screened among newborns across Europe.

Newborn Screening, Pharmacogenetics, and Predispositions & Disorders
The team

People are at the heart of our company. Discover the talents that make up our teams.

Arnaud Allaer

CEO

Axel Collard

CCO

Liselot Detemmerman

CSO

Véronique Distexhe

CAO

Cédric Remy

COO

Axel Collard

CCO

Louisa Cravatte

Direct Sales Manager

Florian Bohet

Area Sales Manager Europe

Ysaline Ghesquière

Area Sales Manager Eurasia

Maria Quiroga

Area Sales Manager Latam

Riccardo Becchetti

Account Manager Italy

Maxime Dewandre

Account Manager Belgium & Switzerland

Anna-Olivia Pasture

Account Manager Germany

Axelle Rogister

Account Manager Austria & UK

Adriana Valenzuela

Account Manager Spain & Portugal

Marine Bellefroid

Product Specialist

Hélène Hiertz

Product Specialist

Nora Benghalem

Business Development

Laura Schoumaker

Marketing Officer

Mathilde Hoferlin

HR & Admin Officer

The Logistics Team

Fabrizio, William, David

LaCAR is constantly evolving and offers a wide range of expertise over a large geographical area.

Belgium
Germany
Switzerland
Portugal
Greece
Sweden
Ireland
Poland
Lituania
Kosovo
Netherlands
France
Spain
Italy
Denmark
Finland
UK
Czech Republic
Slovenia
Estonia
North Macedonia
Serbia
Romania
Croatia
Turkey
Norway
Canada
Mexico
Panama
Argentina
Bolivia
Brazil
Chile
Colombia
Ecuador
Paraguay
Peru
Venezuela
Georgia
India
Indonesia
Israel
Kuwait
Saudi Arabia
Thailand
United Arab Emirates
Vietnam
Egypt
Morocco

Research and Development

Our vision

At LaCAR, we envision a world where everyone benefits from rapid and reliable genetic diagnostics, enabling personalised healthcare while contributing to more equitable and sustainable global public health.

Aware of these challenges, our R&D team is committed to meeting the needs of customers and patients, taking into account the specific recommendations of different countries and continents, as well as advances in academic research and technology.

Contact